Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
തുറക്കുക
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
Q1 2026 earnings • in 4 days
See details
JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
$202.72
-0.15%
(-0.30) 1D
$202.72
0.00% (0.00)
After hours
Closed: മേയ് 1, ജിഎംടി-4 4:00:00 PM  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JAZZ...
തുറക്കുക
$204.50
High
$204.99
Low
$201.75
Mkt. cap
൧൨.൭൨B
Avg. vol.
൮൯൬.൩൨K
Volume
൫൭൨.൩൩K
52-wk high
$207.48
52-wk low
$97.50
EPS
-$5.87
Beta
൦.൨൩
Shares outstanding
൬൨.൭൪M
No. of employees
൩K
News stories
From sources across the web
Stock Titan
Stock Titan
·
1 മണിക്കൂർ മുമ്പ്
Jazz Pharmaceuticals (NASDAQ: JAZZ) reports two 6,000-share Rule 144 sales
TipRanks
TipRanks
·
11 മണിക്കൂർ മുമ്പ്
Why Jazz Pharmaceuticals Stock Is Suddenly Sinking
പ്രൊഫൈൽ
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOബ്രൂസ് സി. കോസഡ്ഡ്
Employees2.89K
Founded2003
Headquarters-
Sector-
Websitejazzpharma.com
Next call 4 ദിവസത്തിൽ
മേയ് 5, ചൊവ്വ, 4:30 PM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (൪.൬൬ est.)USD
Revenue / Estimate
-/ (൯൭൯.൧൬M est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 മാർ
2025 ജൂൺ
2025 സെപ്റ്റം
2025 ഡിസം
Revenue
897.84M
1.05B
1.13B
1.20B
Cost of goods sold
74.74M
116.27M
128.88M
112.92M
Cost of revenue
74.74M
116.27M
128.88M
112.92M
Research and development expenses
180.65M
189.97M
198.20M
172.66M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
514.01M
358.40M
379.15M
418.46M
Operating expense
849.11M
710.47M
745.72M
760.86M
Total operating expenses
923.85M
826.74M
874.60M
873.79M
Operating income
-26.01M
218.97M
251.51M
324.14M
Other non operating income
-
-
-
-
EBT including unusual items
-110.35M
-735.64M
8.99M
208.41M
EBT excluding unusual items
-80.47M
169.72M
202.99M
278.02M
Income tax expense
-17.81M
-17.17M
-242.42M
4.96M
Effective tax rate
16.14%
2.33%
-2,697.20%
2.38%
Other operating expenses
-
-
-
-
Net income
-92.54M
-718.47M
251.41M
203.45M
Net profit margin
-10.31%
-68.71%
22.33%
16.98%
Earnings per share
1.68
-8.25
8.13
6.64
Interest and investment income
-
19.10M
18.60M
20.50M
Interest expense
-53.71M
-66.46M
-67.18M
-65.91M
Net interest expenses
-53.71M
-47.36M
-48.58M
-45.41M
Depreciation and amortization charges
-
-
-
-
EBITDA
138.86M
392.98M
429.76M
503.31M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer